UAE to Introduce Device to Combat Type II Diabetes
The UAE will be the first country worldwide after the US Food and Drug Administration (FDA) to introduce a device to deal with high blood sugar type II. H.E. Dr. Amin Hussein Al Amiri, Assistant Undersecretary for Public Law and Licensing of the Ministry of Health and Prevention(MOHAP) said that the action comes under the Ministry's strategy to deal with the threats associated with diabetes and supply the individuals with latest global therapy systems. The UAE is among the world's prominent countries in the field of drugs, and has developed innovative drugs to combat cancer, viral liver disease, rheumatism, cardiovascular disease, diabetic, high blood pressure and various other illness. The UAE was the 2nd or 3rd in the world to sign up or include these drugs within its solutions after the fostering of international requirements in medicine.
MOHAP has been coordinating with among the biggest French global companies, for the UAE to be the first country in the world to offer the latest medicines for the therapy of type II diabetes mellitus, when accepted by the FDA, in January next year as expected.
The new medication is a small device made from titanium in the dimension of intermediator and is placed under the skin and under the upper body for both males and females. It consists of a micro pump that injects the everyday dosage necessary for the client with type II diabetes frequently and lasts as much as 6 months, and is anticipated to rise to a period of 12 months in mid-2018. This medicine is from a group GLP-1 RA in the body, which then prompts the pancreatic to pump insulin. The first drug of this group is not offered by injection or tablets.
Scientific research and global studies have shown the effectiveness of this medication in lowering blood sugar in addition to weight-loss. Hence, this medicine will certainly aid kind II diabetic patients to adhere to the day-to-day therapeutic dosage, which will certainly aid in managing blood sugar level degrees and stay clear of difficulties triggered by the disease.
